When Yardena Neeman was diagnosed with breast cancer at the age of 47, she decided to take an active role in her diagnosis and treatment decisions. Educating herself on her options, Yardena sought a test that provided insights into the characteristics of her cancer, which ultimately helped her and her doctor make the informed decision to forgo chemotherapy. “The oncologist offered me an alternative path, which in retrospect, changed my whole course of treatment,” Yardena recounted. “The realization that there was really no reason for me to undergo chemotherapy helped me slowly and carefully return to a full life. We must be informed and involved in any decision about treatment.”
On World Cancer Day, Teva is proud to join the Union for International Cancer Control (UICC) in raising awareness of the impact of cancer and urging global action. The United Nations has declared action against non-communicable diseases, including cancer, as critical to achieving the 2030 Sustainable Development Goals. As the global leader in generic and biopharmaceutical medicines, we remain a dedicated partner in these efforts, striving to increase access to affordable medicines and providing innovative evidence-based solutions for untreated and undertreated conditions. We are committed to integrating our generics, biopharmaceutical and specialty capabilities to meet the unmet needs of cancer patients.
Teva also offers more than 40 oncology medicines (84%) listed on the World health Organizations (WHO) Essential Medicine List (EML). For example, between April 2017 and March 2018, we supplied 44 million oncology drug packs – more than half a billion tablets and vials. Our medicines include chemotherapy treatments and medicines targeting cancer-related pain, non-Hodgkin's lymphoma, breast cancer, chronic myeloid leukemia and more.
In the words of Thomas Thoma, Head of Clinical Trial Supply and Global Health Tendering at Teva, “My daily motivation as father of three kids is that nobody should lose a child due to lack of medicine.”
In addition to our broad portfolio of medicines, Teva is dedicated to addressing the burden of cancer around the world through partnerships and programs, including: